G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.

PLoS One 2016 10;11(6):e0157245. Epub 2016 Jun 10.

Diabetes Research Institute, University of Miami, Miami, Florida, United States of America.

Background: Allogeneic human islet transplantation is an effective therapy for the treatment of patients with Type 1 Diabetes (T1D). The low number of islet transplants performed worldwide and the different transplantation protocols used limit the identification of the most effective therapeutic options to improve the efficacy of this approach.

Methods: We present a retrospective analysis on the data collected from 44 patients with T1D who underwent islet transplantation at our institute between 2000 and 2007. Several variables were included: recipient demographics and immunological characteristics, donor and transplant characteristics, induction protocols, and additional medical treatment received. Immunosuppression was induced with anti-CD25 (Daclizumab), alone or in association with anti-tumor necrosis factor alpha (TNF-α) treatments (Etanercept or Infliximab), or with anti-CD52 (Alemtuzumab) in association with anti-TNF-α treatments (Etanercept or Infliximab). Subsets of patients were treated with Filgrastim for moderate/severe neutropenia and/or Exenatide for post prandial hyperglycemia.

Results: The analysis performed indicates a negative association between graft survival (c-peptide level ≥ 0.3 ng/ml) and islet infusion volume, with the caveat that, the progressive reduction of infusion volumes over the years has been paralleled by improved immunosuppressive protocols. A positive association is instead suggested between graft survival and administration of Exenatide and Filgrastim, alone or in combination.

Conclusion: This retrospective analysis may be of assistance to further improve long-term outcomes of protocols for transplant of islets and other organs.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157245PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902232PMC
July 2017
26 Reads

Publication Analysis

Top Keywords

retrospective analysis
8
islet transplantation
8
graft survival
8
treatments etanercept
8
etanercept infliximab
8
islet
5
additional medical
4
medical treatment
4
protocols additional
4
characteristics induction
4
induction protocols
4
volumes years
4
infusion volumes
4
treatment received
4
induced anti-cd25
4
anti-cd25 daclizumab
4
association
4
progressive reduction
4
immunosuppression induced
4
received immunosuppression
4

References

(Supplied by CrossRef)
Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges
A Bruni et al.
Diabetes Metab Syndr Obes 2014

Similar Publications